Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years

(MedPage Today) -- CHICAGO -- Patients with advanced non-small cell lung cancer (NSCLC) who are progression-free may discontinue treatment with frontline immunotherapy after 2 years without compromising overall survival (OS), a retrospective...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news